CytoMed Therapeutics
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- -
- Employees
- 34
- Market Cap
- $18.3M
- Introduction
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
Phase 1
Recruiting
- Conditions
- MalignancyRelapsed CancerCancerRefractory Cancer
- Interventions
- Biological: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- CytoMed Therapeutics Pte Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05302037
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
Phase 1
- Conditions
- Prostate CancerColorectal CancerTriple Negative Breast CancerGastric CancerSarcomaNasopharyngeal Carcinoma
- Interventions
- Biological: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- CytoMed Therapeutics Pte Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT04107142
- Locations
- 🇲🇾
Landmark Medical Centre, Johor Bahru, Johor, Malaysia
© Copyright 2025. All Rights Reserved by MedPath